key: cord-0710416-syjkxqvg
authors: Mazori, Alon Y.; Bass, Ilana Ramer; Chan, Lili; Mathews, Kusum S.; Altman, Deena; Saha, Aparna; Soh, Howard; Wen, Huei Hsun; Bose, Sonali; Leven, Emily; Wang, Jing Gennie; Mosoyan, Gohar; Pattharanitima, Pattharawin; Greco, Giampaolo; Gallagher, Emily J.
title: Hyperglycemia is Associated with Increased Mortality in Critically Ill Patients with COVID-19
date: 2021-01-09
journal: Endocr Pract
DOI: 10.1016/j.eprac.2020.12.015
sha: fbdca7b088bd06bea1bfb317ec1606d87a34c53b
doc_id: 710416
cord_uid: syjkxqvg

OBJECTIVE: To explore the relationship between hyperglycemia in the presence and absence of diabetes mellitus (DM) and adverse outcomes in critically ill patients with coronavirus disease 2019 (COVID-19). METHODS: The study population comprised 133 patients with COVID-19 admitted to an intensive care unit (ICU) at an academic, urban, quaternary-care center between March 10 and April 8, 2020. Patients were categorized based on the presence of DM and early-onset hyperglycemia (EHG), defined as a blood glucose >180 mg/dL during the first two days of ICU admission. The primary outcome was 14-day, all-cause, in-hospital mortality; also examined were 60-day, all-cause, in-hospital mortality and the levels of C-reactive protein (CRP), interleukin 6, procalcitonin, and lactate. RESULTS: Compared to non-DM patients without EHG, non-DM patients with EHG exhibited higher adjusted hazard ratios (HR) for mortality at 14 days (HR 7.51, confidence interval [CI] 1.70-33.24) and 60 days (HR 6.97, CI 1.86-26.13). Non-DM patients with EHG also featured higher levels of median CRP (306.3 mg/L, p=0.036), procalcitonin (1.26 ng/mL, p=0.028), and lactate (2.2 mmol/L, p=0.023). CONCLUSION: In patients with critical illness from COVID-19, those without DM with EHG were at greatest risk of 14-day and 60-day in-hospital mortality. The limitations of our study include its retrospective design and relatively small cohort. However, our results suggest that the combination of elevated glucose and lactate may identify a specific cohort of individuals at high mortality risk from COVID-19, and suggest that glucose testing and control are important in individuals with COVID-19, even in those without pre-existing diabetes.

higher adjusted hazard ratios (HR) for mortality at 14 days (HR 7.51, confidence interval [CI] 48 1.70-33.24) and 60 days (HR 6.97, CI 1.86-26.13). Non-DM patients with EHG also featured 49 higher levels of median CRP (306.3 mg/L, p=0.036), procalcitonin (1.26 ng/mL, p=0.028), and 50 lactate (2.2 mmol/L, p=0.023). In the era before COVID-19, studies of acutely ill, hospitalized individuals with stroke, 72 myocardial infarction, trauma, and burns reported that hyperglycemia increased mortality risk 73 and complications to a greater extent in individuals without DM than in those with DM (9-12). 74 Similarly, individuals without DM with hyperglycemia admitted to neurosurgical, cardiac, or 75 cardiothoracic intensive-care units had greater mortality (13). We conducted this observational 76 study to determine if hyperglycemia in the presence or absence of pre-existing DM was 77 associated with mortality risk in critically ill patients with COVID-19. (ICD)-9 or -10 diagnosis code, or the presence of a hemoglobin A1c (HbA1c) at any time prior 93 to ICU admission of ≥6.5%. Pre-diabetes was defined as a having a diagnosis of pre-diabetes in 94 the medical record or a HbA1c of 5.7-6.4%. The type of anti-hyperglycemic medication used 95 prior to admission was also recorded. Maximum glucose values, C-reactive protein (CRP), 96 creatinine, D-dimer, ferritin, interleukin 6 (IL-6), lactate, and procalcitonin levels were recorded 97 for the first 48 hours of ICU admission. Interventions, including the type of respiratory support 98 and use of glucocorticoids during the ICU admission, were also recorded. given ICU day, then the TDI was recorded as zero. The TDI dose for each patient was then 112 corrected for body weight by dividing TDI (IU) by weight (kg) to give the corrected TDI (cTDI).

Data were collected until hospital discharge, death, or completion of the 14-day interval, even if 114 a patient was transferred out of the ICU during the 14-day follow-up period.

The primary outcome of this study was 14-day, all-cause, in-hospital mortality in patients 116 with and without diabetes who did or did not experience EHG. We also analyzed all-cause, in-117 hospital mortality at 60 days. The relationship between EHG in the presence or absence of 118 diabetes, TDI, hyperlactatemia, and evidence of inflammatory response (CRP, D-dimer, ferritin, 119 IL-6, and procalcitonin) were also examined. 

Baseline characteristics for the overall cohort (n=133) and those with and without pre-139 existing DM are shown in Table 1 . The mean age of the entire cohort was 59 (± 14) years, and a 140 majority (69%) were male. The mean BMI was 31.4 (±7.9) kg/m 2 . Obesity affected 43.6% of 141 patients, while 32.3% were overweight. Two (1.5%) subjects had previously diagnosed T1DM, 142 44 (33.1%) had a diagnosis of T2DM, and an additional 16 (12.0%) had an HbA1c ≥6.5% prior 143 to ICU admission and were included in the DM group in further analyses. The most common co-144 morbidity was hypertension, which was observed in 55 (41.4%) of patients.

J o u r n a l P r e -p r o o f Individuals with DM were older than those without DM (63±12 vs. 56±15 years, 146 p=0.007), and had a higher prevalence of hypertension (51.6% vs. 32.4%, p=0.025), coronary 147 artery disease (21.6% vs. 8.5%, p=0.040), and congestive heart failure (12.9% vs. 2.8%, 148 p=0.028). Neither BMI nor the burden of CKD was different between patients with and without 149 DM. The mean pre-ICU HbA1c for patients with DM was 7.5±2.0% (58±22 mmol/mol). The Table 2 shows the characteristics of those who developed EHG, compared with those 155 who did not, in the DM and non-DM groups. In the group with DM, those who had EHG had To understand why EHG might be associated with mortality in the group without DM, include its single-center design and smaller sample size, both of which limit the generalizability 244 of our findings and limit our statistical power in some subgroups to detect significant differences.

Further investigation is necessary to determine whether our results can be replicated in other ICU 246 cohorts of patients with COVID-19. 247 Overall, our data showed that, in critically ill patients with COVID-19, those without DM 248 with EHG had significantly increased mortality and higher levels of inflammatory markers. Our Other 10 (17.9%) 0 (0%) 3 (20.0%) 2 (4.3%) Data are expressed as either mean±SD or counts (percentage). Superscripts indicate significant pairwise differences between subgroups. Significance was determined by Tukey's honestly significant difference (HSD) post-hoc tests for continuous and normally distributed data, Dunn-Bonferroni post-hoc method for continuous and non-normally distributed data, and adjusted standardized residuals for categorical data. *Laboratory data are maximum values between ICU calendar days 1 and 2, and expressed as median (interquartile range). Abbreviations: BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; DM, diabetes mellitus; EHG, early-onset hyperglycemia; ESRD on RRT, end-stage renal disease on renalreplacement therapy; HDL, high-density lipoprotein; HFNC, high-flow nasal cannula; IMV, invasive mechanical ventilation; LDL, low-density lipoprotein; NRB, non-rebreather mask. 

Association of Blood Glucose 266 Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized 270 With COVID-19 in the New York City Area

The impact of type 2 diabetes and its 272 management on the prognosis of patients with severe COVID-19

Newly diagnosed diabetes is 274 associated with a higher risk of mortality than known diabetes in hospitalized patients with 275 COVID-19

J-shaped association between fasting 277 blood glucose levels and COVID-19 severity in patients without diabetes

Fasting blood glucose predicts the 280 occurrence of critical illness in COVID-19 patients: A multicenter retrospective cohort study

Fasting Plasma Glucose 283

Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: 284 A Multicenter, Retrospective Cohort Study. Endocrinol Metab (Seoul). 2020. 285 8. Carrasco-Sanchez FJ

Admission hyperglycaemia as a predictor of mortality in 287 patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-288 COVID-19 Registry

Stress hyperglycaemia and increased risk 293 of death after myocardial infarction in patients with and without diabetes: a systematic overview

Stress-induced hyperglycemia, not 296 diabetic hyperglycemia, is associated with higher mortality in trauma

Admission 299

Hyperglycemia Predicts Infectious Complications After Burns

Impact of 302 admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit 303 Care Med

Intensive 308 versus conventional glucose control in critically ill patients

Elevation of blood glucose level 311 predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study

Newly-diagnosed 314 diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory 315 deterioration

2020:e3319. 318 19. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk 319 factor for long-term prognosis after myocardial infarction even in nondiabetic patients

Determinants and importance of 322 stress hyperglycaemia in non-diabetic patients with myocardial infarction

Glycemic control in non-diabetic critically ill 325 patients

COVID-19 and Diabetes: The Importance of 327 Controlling RAGE

Hyperglycemia in Critically Ill Patients: Insight Into Possible Molecular Pathways

Hyperlactatemia 332 affects the association of hyperglycemia with mortality in nondiabetic adults with sepsis

Lactate induces insulin 337 resistance in skeletal muscle by suppressing glycolysis and impairing insulin signaling

Lactate, a Neglected Factor for 340 Diabetes and Cancer Interaction

Intensive insulin therapy in critically ill patients

Prospective randomised study of intensive insulin treatment on long term 344 survival after acute myocardial infarction in patients with diabetes mellitus

Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

348 Intensive insulin therapy and pentastarch resuscitation in severe sepsis

Outcomes 351 in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? 352 Diabetes Care

J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f